Literature DB >> 1977779

Relation between beta-adrenergic blocker use, various correlates of left ventricular function and the chance of developing congestive heart failure. The Multicenter Diltiazem Post-Infarction Research Group.

E Lichstein1, W D Hager, J J Gregory, J L Fleiss, L M Rolnitzky, J T Bigger.   

Abstract

This study examined the relations among beta-adrenergic blocker use, various correlates of left ventricular function and the chance of developing congestive heart failure in patients after myocardial infarction. The study was performed with the placebo group of the Multicenter Diltiazem Post-Infarction Trial. Ejection fraction data were available in 1,084 patients; of these, 557 were receiving a beta-blocker and 527 were not. In addition to ejection fraction, other correlates of left ventricular function included the presence or absence of pulmonary rales, chest X-ray film evidence of pulmonary congestion and the presence of an S3 gallop. Beta-blocker use was less frequent in patients with an ejection fraction less than 30%, rales, an S3 gallop and pulmonary congestion on chest X-ray film. Twenty-one percent of patients with an ejection fraction less than 30%, 42% of patients with rales, 28% of patients with an S3 gallop and 28% of patients with pulmonary congestion were receiving beta-blocker therapy. For every correlate of left ventricular function, the chance of developing congestive heart failure was greater in patients with diminished left ventricular function than in those without. For each level of left ventricular function, the chance of developing congestive heart failure requiring treatment was greater in patients not taking a beta-blocker.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1977779     DOI: 10.1016/0735-1097(90)90372-v

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  12 in total

1.  beta blocker treatment and other prognostic variables in patients with clinical evidence of heart failure after acute myocardial infarction: evidence from the AIRE study.

Authors:  K S Spargias; A S Hall; D C Greenwood; S G Ball
Journal:  Heart       Date:  1999-01       Impact factor: 5.994

Review 2.  Should calcium antagonists be used after myocardial infarction? Ischemia selectivity versus vascular selectivity.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1992-02       Impact factor: 3.727

Review 3.  To dig or not to dig.

Authors:  G R Dagenais; J M Brophy
Journal:  Trans Am Clin Climatol Assoc       Date:  1998

Review 4.  Calcium channel antagonists should be among the first-line drugs in the management of cardiovascular disease.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1996-09       Impact factor: 3.727

Review 5.  Treatments that improve outcome in the patient with heart failure, left ventricular systolic dysfunction, or both after acute myocardial infarction.

Authors:  R Weir; J J V McMurray
Journal:  Heart       Date:  2005-05       Impact factor: 5.994

6.  Cardiac remodelling.

Authors:  L B Tan; A S Hall
Journal:  Br Heart J       Date:  1994-10

Review 7.  Controversies surrounding the use of beta-blockers in older patients with cardiovascular disease.

Authors:  R W Jansen; J H Gurwitz
Journal:  Drugs Aging       Date:  1994-03       Impact factor: 3.923

Review 8.  Postinfarction use of beta-blockers in elderly patients.

Authors:  W S Aronow
Journal:  Drugs Aging       Date:  1997-12       Impact factor: 3.923

Review 9.  Calcium antagonists post-infarction: the significance of experimental studies on potentially lethal early ischemic ventricular arrhythmias.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1991-08       Impact factor: 3.727

10.  Secondary prevention with calcium antagonists after acute myocardial infarction.

Authors:  J F Hansen
Journal:  Drugs       Date:  1992       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.